Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board meeting held on August 13, 2025.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Ind-Swift Laboratories approved standalone and consolidated unaudited financial results for the quarter ended June 30, 2025. On a consolidated basis, revenue from operations rose modestly to Rs 152.73 crore (vs Rs 147.02 crore in Q1 FY25), but net profit fell sharply to Rs 8.77 crore from Rs 29.17 crore in the year-ago quarter, a drop of nearly 70%. Standalone net profit also declined steeply to Rs 8.12 crore from Rs 34.43 crore, even as revenue was largely flat at around Rs 148 crore. The company disclosed that the scheme of amalgamation merging Ind-Swift Limited into Ind-Swift Laboratories became effective on August 8, 2025, with the appointed date of March 31, 2024. As part of this, ISLL will issue 81,24,698 equity shares to eligible ISL shareholders, with the record date set for August 14, 2025. Comparative figures have been restated to reflect the merger. The statutory auditor, M/s Rattan Kaur & Associates, issued an unqualified limited review report on both standalone and consolidated results.
The sharp year-on-year drop in quarterly profit, despite stable revenue, is a negative signal for the stock and may raise investor concerns about margin pressure and cost growth. The share issuance of over 81 lakh new equity shares to ISL shareholders will result in modest equity dilution for existing shareholders of Ind-Swift Laboratories.